DrugPatentWatch Database Preview
Eculizumab - Biologic Drug Details
» See Plans and Pricing
Summary for eculizumab
| Tradenames: | 1 |
| Patents: | 87 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for eculizumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for eculizumab |
Recent Clinical Trials for eculizumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Hoffmann-La Roche | Phase 3 |
| Chugai Pharmaceutical | Phase 3 |
| Assistance Publique - Hôpitaux de Paris | Phase 2 |
Recent Litigation for eculizumab
Identify key patents and potential future biosimilar entrants
PTAB Litigation
| Petitioner | Date |
|---|---|
| Amgen Inc. | 2019-02-28 |
| Amgen, Inc. | 2019-02-28 |
| 2017-12-20 |
Pharmacology for eculizumab
| Mechanism of Action | Complement Inhibitors |
Company Disclosures: US Patents for eculizumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Alexion Pharmaceuticals, Inc. (Cheshire, CT) | 2019-03-12 | RX | Orphan | company |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Alexion Pharmaceuticals, Inc. (New Haven, CT) | 2027-03-15 | RX | Orphan | company |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Alexion Pharmaceuticals, Inc. (New Haven, CT) | 2027-03-15 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for eculizumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Janssen Pharmaceutica NV (Beerse, BE) | 2028-03-27 | RX | Orphan | search |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Aegis Therapeutics LLC (San Diego, CA) | 2026-06-23 | RX | Orphan | search |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Teva Pharmaceuticals Industries, Ltd. (Petach-Tikva, IL) | 2028-09-03 | RX | Orphan | search |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | ForSight Vision4, Inc. (Menlo Park, CA) | 2029-01-29 | RX | Orphan | search |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Massachusetts Institute of Technology (Cambridge, MA) | 2028-10-23 | RX | Orphan | search |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | Forsight Vision4, Inc. (Menlo Park, CA) | 2029-01-29 | RX | Orphan | search |
| Alexion Pharm | SOLIRIS | eculizumab | INJECTABLE; IV (INFUSION) | 125166 | 001 | 2007-03-16 | Start Trial | AbbVie, Inc. (North Chicago, IL) | 2027-11-30 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for eculizumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102005562 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012019176 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013120066 | Start Trial |
| Brazil | PI0713923 | Start Trial |
| Taiwan | 200938221 | Start Trial |
| China | 103501815 | Start Trial |
| Japan | 2012531431 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for eculizumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0758904/01 | Switzerland | Start Trial | FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH |
| 2009000075 | Germany | Start Trial | PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620 |
| 12/2010 | Austria | Start Trial | PRODUCT NAME: ECULIZUMAB |
| 2010901820871 | Italy | Start Trial | PRODUCT NAME: ECULIZUMAB(SOLIRIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/393/001, 20070620 |
| C/GB10/015 | United Kingdom | Start Trial | PRODUCT NAME: ECULIZUMAB; REGISTERED: UK EU/1/07/393/001 20070620 |
| C002/2010 | Ireland | Start Trial | SPC002/2010: 20100902, EXPIRES: 20200430 |
| C0016 | France | Start Trial | PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
